Read more
This five-volume series provides clinicians with a detailed, up-to-date, well-referenced overview of the latest developments in this rapidly expanding field. It serves as an authoritative guide to the diagnosis and treatment of platelet disorders.The primary audience for the series is clinicians, residents and fellows in internal medicine, cardiology and haematology, as well as clinicians (e.g. neurologists, nephrologists, rheumatologists) and basic scientists who may be concerned with disorders and cellular mechanisms involving platelets.
List of contents
Chapter 1: Platelets: a historical view.- Chapter 2: Phylogeny of blood platelets.- Chapter 3: Platelet morphology and ultrastructure.- Chapter 4: Intramedullary Megakaryopoiesis.- Chapter 5: Extramedullary Megakaryopoiesis.- Chapter 6: Inherited and acquired defects of megakaryopoiesis and thrombopoiesis.- Chapter 7: Alternative functions of megakaryocytes.- Chapter 8: Advances in Megakaryocyte Imaging Technology.- Chapter 9: Advances and Challenges in the Ex Vivo Production of Megakaryocytes and Platelets.- Chapter 10: Platelet adhesion receptors.- Chapter 11: Glycoprotein Ib/IX/V.- Chapter 12: Integrin IIb 3.- Chapter 13: Glycoprotein VI.- Chapter 14: CLEC-2.- Chapter 15: Platelet FcyRIIa receptor.- Chapter 16: Protease activated receptors.- Chapter 17: Platelet Thromboxane A2 and prostanoid receptors.- Chapter 18: Purinergic P2 receptors.- Chapter 19: ITIM containing receptors.- Chapter 20: Platelet glycans.- Chapter 21: The platelet cytoskeleton.- Chapter 22: The platelet proteome.- Chapter 23. The platelet lipidome.- Chapter 24: The platelet transcriptome: coding RNAs.- Chapter 25: The platelet transcriptome: non-coding RNAs.- Chapter 26: Platelet genomics.- Chapter 27: Platelet signal transduction: GTPase.- Chapter 28: Platelet signal transduction: calcium.- Chapter 29: Platelets signal transduction: focal adhesion kinases.- Chapter 30: Platelet signaling: protein phosphorylation.
About the author
Prof. Paolo Gresele, MD, PhD, is Professor of Internal Medicine at the Department of Medicine and Surgery of the University of Perugia, Italy. His research interests are mainly focused on hemostatic and thrombotic disorders, with special attention on the role of platelets in hemorrhagic, cardiovascular and inflammatory diseases. He has been President of Italian Society on Hemostasis and Thrombosis, former chair of the Platelet Physiology Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH) he is member of the panel of experts on ClinGen Hemostasis/Thrombosis Clinical Domain Working Group and is the current Chair of the Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders of the European Hematology Association (EHA-SWG).
Dr. José A. López, MD has held academic positions at the University of California, San Francisco and Gladstone Institute for Cardiovascular Disease, at the Baylor College of Medicine in Houston, Texas, and, most recently, at the University of Washington, where he holds the title of Professor of Medicine (Hematology) and Adjunct Professor of Biochemistry and Mechanical Engineering. Dr. López is also Chief Scientific Officer of Bloodworks Northwest, a large regional blood center, and directs the Bloodworks Research Institute, where he also runs an active laboratory.
Dr. López is currently serving as Co-Director of the Translational Research Training in Hematology Program, an international program to assist in fellow-to-faculty transition cosponsored by the European Hematology Association and the American Society of Hematology.
Prof. Dominick J. Angiolillo, MD, PhD. is a Distinguished Professor of Medicine with Tenure status, Chief of Cardiology and Medical Director of the University of Florida Health Cardiovascular Center. He is also the Medical Director of Cardiovascular Research, Program Director of the ACGME-accredited Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Much of Prof. Angiolillo’s professional career has been devoted to interventional cardiology and management of patients with acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis, being a key investigator in the clinical development of numerous novel antithrombotic agents for which he has received numerous national and international academic recognitions.
Professor Clive Page, OBE, BSc, PhD, FRSB, FBPhs (Hon), FFPM (Hon) is an Emeritus Professor of Pharmacology, King’s College London. His main research interests are in the pharmacology of inflammation and respiratory disease. Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company and was instrumental in the discovery and development of Ensifentrine for the treatment of COPD and other respiratory diseases which was recently approved by the FDA. Clive is a recent past President of the British Pharmacological Society and was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Royal Society of Biology President’s Medal in 2012 for “Outstanding Contributions to the Life Sciences”.
